Daniel V Carter

US Patent:

6787636, Sep 7, 2004

Filed:

Jul 14, 2000

Appl. No.:

09/616962

Inventors:

Daniel C. Carter - Madison AL

Assignee:

New Century Pharmaceuticals, Inc. - Huntsville AL

International Classification:

C07K 100

US Classification:

530363, 530324, 530362, 435 691, 435 696, 435 711, 4352523

Abstract:

A modified serum albumin is provided which has been modified in the n-terminal region or binding region VI, such as through a truncation of at least one amino acid at the n-terminal end, so that it exhibits reduced or eliminated binding of trace metals such as nickel and/or copper. Other suitable modifications to this binding region include mutations such as an elongation or insertion which will be sufficient to disrupt the trace metal binding which is highest at this site. The modified albumin of the present invention is advantageous in that it is binding to trace metals is reduced or eliminated, and it can thus be used more safely and effectively than unmodified albumin with a reduced or eliminated likelihood of causing an allergic reaction to the trace metal in the human being treated with the albumin composition.

US Patent:

6949691, Sep 27, 2005

Filed:

Jun 17, 2002

Appl. No.:

10/171688

Inventors:

Daniel C. Carter - Huntsville AL, US

Assignee:

New Century Pharmaceuticals Inc. - Huntsville AL

International Classification:

A01K067/027
G01N033/00

US Classification:

800 18, 800 3

Abstract:

An animal model is provided which is genetically engineered to express human serum albumin, and such animals may be advantageously used in assessing drugs, vaccines or other therapeutic compounds that may be used in humans. In addition, an animal model is provided which does not manufacture its own albumin and which has been injected with human serum albumin. Through the use of these animal models, drugs and other chemicals can be more accurately assessed in physiological environments that reflect the conditions to be expected in humans, and such models will be useful in assessing new drugs and evaluating toxic substances for potential dangers as carcinogens, mutagens, etc. Other applications include evaluating immunological properties of various albumin-engineered proteins which might be administered to humans as therapeutics or vaccines, and research of disease states, such as genetic diseases, to provide further insight in treating these diseases.

US Patent:

7097841, Aug 29, 2006

Filed:

May 12, 2003

Appl. No.:

10/435666

Inventors:

Daniel C. Carter - Huntsville AL, US
Chester Q. Li - Madison AL, US

Assignee:

New Century Pharmaceuticals, Inc. - Huntsville AL

International Classification:

A61K 39/12
A61K 39/395
C07K 19/00
C12N 15/62

US Classification:

4241921, 4241851, 4241861, 4241881, 4242211, 4241781, 4241341, 530350, 530400, 5303873, 514 2, 514 6, 536 234

Abstract:

An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or an exocapsid form when fused at the N terminus. These fusion proteins may self-assemble into a variety of useful higher polymeric forms, e. g. , capsid or other polymeric aggregate, and they are advantageous in that they are useful in a variety of applications, including human and veterinary vaccines and therapeutics, blood substitutes, image contrast agents, metal chelating agents, gelling agents, protein purification platforms, and therapeutic receptor-binding proteins.

US Patent:

7179838, Feb 20, 2007

Filed:

Jul 30, 2003

Appl. No.:

10/629858

Inventors:

Daniel C. Carter - Huntsville AL, US

Assignee:

New Century Pharmaceuticals, Inc. - Huntsville AL

International Classification:

A61K 31/352
C07D 311/52

US Classification:

514457, 549286

Abstract:

The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

US Patent:

7208580, Apr 24, 2007

Filed:

Mar 3, 2003

Appl. No.:

10/506043

Inventors:

Daniel C. Carter - Huntsville AL, US
Joseph Ho - Madison AL, US
Zhong Min Wang - Madison AL, US

Assignee:

New Century Pharmaceuticals, Inc. - Huntsville AL

International Classification:

C07K 14/76
C07K 14/795
G01N 23/207

US Classification:

530362, 530363, 540145, 540201, 378 73

Abstract:

A high resolution structure of the hemalbumin binding complex is provided which includes the detailed atomic coordinates which reflect the binding site and the binding characteristics of the structure. This high resolution structure can be used in methods of determining the primary residues involved in gas binding, redox potential of iron, etc. , and thus will be used to identify and optimize the gas binding characteristics of heme and albumin, so as to allow for the development of modified recombinant albumins containing heme and/or heme derivatives which have improved gas binding properties and which can be used for therapeutic purposes.

US Patent:

7253147, Aug 7, 2007

Filed:

Sep 7, 2004

Appl. No.:

10/934401

Inventors:

Daniel C. Carter - Madison AL, US

Assignee:

New Century Pharmaceuticals, Inc. - Huntsville AL

International Classification:

A61K 38/38
C07K 14/765

US Classification:

514 12, 530363

Abstract:

A modified serum albumin is provided which has been modified in the n-terminal region or binding region VI, such as through a truncation of at least three amino acids at the n-terminal end, so that it exhibits reduced or eliminated binding of trace metals such as nickel and/or copper. Other suitable modifications to this binding region include mutations such as an elongation or insertion which will be sufficient to disrupt the trace metal binding which is highest at this site. The modified albumin of the present invention is advantageous in that its binding to trace metals is reduced or eliminated, and it can thus be used more safely and effectively than unmodified albumin with a reduced or eliminated likelihood of causing an allergic reaction to the trace metal in the human being treated with the albumin composition.

US Patent:

7439077, Oct 21, 2008

Filed:

Feb 20, 2007

Appl. No.:

11/708004

Inventors:

Daniel C. Carter - Huntsville AL, US

Assignee:

New Century Pharmaceuticals, Inc. - Huntsville AL

International Classification:

G01N 33/566
A61K 31/37

US Classification:

436501, 514457, 549285

Abstract:

The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

US Patent:

7608268, Oct 27, 2009

Filed:

Mar 14, 2006

Appl. No.:

11/374066

Inventors:

Daniel C. Carter - Huntsville AL, US
Chester Q. Li - Madison AL, US

Assignee:

New Century Pharmaceuticals, Inc. - Huntsville AL

International Classification:

A61K 39/12
A61K 39/395
C07K 19/00
C12N 15/62

US Classification:

4241921, 4241851, 4241861, 4241881, 4242211, 4241781, 4241344, 530350, 530400, 5303873, 514 2, 514 6, 536 234, 435262

Abstract:

An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or an exocapsid form when fused at the N terminus. These fusion proteins may self-assemble into a variety of useful higher polymeric forms, e. g. , capsid or other polymeric aggregate, and they are advantageous in that they are useful in a variety of applications, including human and veterinary vaccines and therapeutics, blood substitutes, image contrast agents, metal chelating agents, gelling agents, protein purification platforms, and therapeutic receptor-binding proteins.